Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 67Breast Neoplasms, Male 4Neoplasm Metastasis 3Neoplasms 2Advanced Breast Cancer 2Unilateral Breast Neoplasms 1Sleep Wake Disorders 1Recurrence 1Ovarian Neoplasms 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1First Line Metastatic Breast Cancer 1Fatigue 1Carcinoma, Intraductal, Noninfiltrating 1Bulbo-Spinal Atrophy, X-Linked 1Breast Carcinoma In Situ 1Breast Cancer Metastatic 1Breast Cancer Female 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Fulvestrant 5Anastrozole 5Letrozole 3exemestane 2Goserelin 2ribociclib 1palbociclib 1entinostat 1elacestrant 1apatinib 1abemaciclib 1Selective Estrogen Receptor Modulators 1RAD1901 1Paclitaxel 1Injections 1Gonadotropin-Releasing Hormone 1FCN-437c 1Everolimus 1Aromatase Inhibitors 1AZD9833 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Advanced Breast Cancer × exemestane × Clear all
NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting
500 enrolled
Breast

Advanced Breast Cancer

NCT03538171 2021-07-09

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

Taizhou EOC Pharma Co., Ltd.

Phase 3 Unknown
375 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡